Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Heather L Gelhorn, Beatrice Osumili, Katelyn Brown, Melissa M Ross, Andrea Schulz, Gabriela Fernandez & Kristina S Boye. (2023) The Impact of Substantial Improvements in HbA1c and Weight Loss on the Medication Preferences of People with Type 2 Diabetes. Patient Preference and Adherence 17, pages 793-805.
Read now
Read now
Tracy J Sims, Kristina S Boye, Susan Robinson & Tessa Kennedy-Martin. (2022) Treatment-Related Attributes of Diabetes Therapies and How People with Type 2 Diabetes Report Their Impact on Indicators of Medication-Taking Behaviors. Patient Preference and Adherence 16, pages 1919-1939.
Read now
Read now
Ariana M Chao, Jena Shaw Tronieri, Anastassia Amaro & Thomas A Wadden. (2022) Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations. Drug Design, Development and Therapy 16, pages 4449-4461.
Read now
Read now
Stephen A. Brunton & Carol H. Wysham. (2020) GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date. Postgraduate Medicine 132:sup2, pages 3-14.
Read now
Read now
Articles from other publishers (20)
Tim Heise, Jenny Chien, John M. Beals, Charles Benson, Oliver Klein, Julie S. Moyers, Axel Haupt & Edward John Pratt. (2023) Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once‐weekly dosing for the treatment of patients with diabetes. Diabetes, Obesity and Metabolism 25:4, pages 1080-1090.
Crossref
Crossref
Irene Romera, Miriam Rubio-de Santos, Sara Artola, Carmen Suárez Fernández & Ignacio Conget. (2023) GLP-1 RAs in Spain: A Short Narrative Review of Their Use in Real Clinical Practice. Advances in Therapy 40:4, pages 1418-1429.
Crossref
Crossref
Ileana Pantea, Nadinne Roman, Angela Repanovici & Daniela Drugus. (2022) Diabetes Patients’ Acceptance of Injectable Treatment, a Scientometric Analysis. Life 12:12, pages 2055.
Crossref
Crossref
Jay H. Shubrook, Michael Radin, Sarah N. Ali, Barrie Chubb, Kristina DiPietrantonio, Hannah Collings, Robin Wyn & Martina Smith. (2022) Preference for Type 2 Diabetes Therapies in the United States: A Discrete Choice Experiment. Advances in Therapy 39:9, pages 4114-4130.
Crossref
Crossref
Ayman A. Al Hayek & Mohamed A. Al Dawish. (2022) Evaluation of Patient-Reported Satisfaction and Clinical Efficacy of Once-Weekly Semaglutide in Patients with Type 2 Diabetes: An Ambispective Study. Advances in Therapy 39:4, pages 1582-1595.
Crossref
Crossref
José L. Górriz, Irene Romera, Amelia Cobo, Phillipe D. O’Brien & Juan F. Merino-Torres. (2022) Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations. Diabetes Therapy 13:3, pages 389-421.
Crossref
Crossref
Qingyang Shi, Yang Wang, Qiukui Hao, Per Olav Vandvik, Gordon Guyatt, Jing Li, Zhe Chen, Shishi Xu, Yanjiao Shen, Long Ge, Feng Sun, Ling Li, Jiajie Yu, Kailei Nong, Xinyu Zou, Siyi Zhu, Cong Wang, Shengzhao Zhang, Zhi Qiao, Zhongyu Jian, Ya Li, Xinyi Zhang, Kerun Chen, Furong Qu, Yuan Wu, Yazhou He, Haoming Tian & Sheyu Li. (2022) Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. The Lancet 399:10321, pages 259-269.
Crossref
Crossref
Erin R. Weeda, Alyssa K. Muraoka, Matthew D. Brock & Jessica M. Cannon. (2021) Medication adherence to injectable glucagon‐like peptide‐1 (GLP‐1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: A meta‐analysis. International Journal of Clinical Practice 75:9.
Crossref
Crossref
Kristina S. Boye, Jessica B. Jordan, Raleigh E. Malik, Brooke M. Currie & Louis S. Matza. (2021) Patient Perceptions of and Preferences Between Characteristics of Injectable Diabetes Treatments. Diabetes Therapy 12:9, pages 2387-2403.
Crossref
Crossref
José Gerardo González-González, Alejandro Díaz González-Colmenero, Juan Manuel Millán-Alanís, Lyubov Lytvyn, Ricardo Cesar Solis, Reem A Mustafa, Suetonia C Palmer, Sheyu Li, Qiukui Hao, Neri Alejandro Alvarez-Villalobos, Per Olav Vandvik & René Rodríguez-Gutiérrez. (2021) Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a systematic review. BMJ Open 11:7, pages e049130.
Crossref
Crossref
Juris J. Meier. (2021) Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation. Frontiers in Endocrinology 12.
Crossref
Crossref
Sarah Zimner Rapuch, Victoria Divino, Kirsi Norrbacka, Kristina Boye, Jeremie Lebrec, Myriam Rosilio, Mitch DeKoven & Bruno Guerci. (2021) Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis. Diabetes Therapy 12:5, pages 1553-1567.
Crossref
Crossref
Kirsi Norrbacka, Antoni Sicras-Mainar, Jeremie Lebrec, Esther Artime, Silvia Díaz, Santiago Tofé-Povedano, Ignacio Hernández & Irene Romera. (2021) Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain. Diabetes Therapy 12:5, pages 1535-1551.
Crossref
Crossref
Diana M. Isaacs, Davida F. Kruger & Geralyn R. Spollett. (2021) Optimizing Therapeutic Outcomes With Oral Semaglutide: A Patient-Centered Approach. Diabetes Spectrum 34:1, pages 7-19.
Crossref
Crossref
Akshay B. Jain, Amar Ali, Juan J. Gorgojo Martínez, Irene Hramiak, Ketan Kavia, Sten Madsbad, Louis Potier, Ben D. Prohaska, Jodi L. Strong & Tina Vilsbøll. (2020) Switching between GLP‐1 receptor agonists in clinical practice: Expert consensus and practical guidance. International Journal of Clinical Practice 75:2.
Crossref
Crossref
Ataru Igarashi, Brian Bekker Hansen, Jakob Langer, Francesca Tavella, Hannah Collings, Neil Davies & Robin Wyn. (2020) Preference for Oral and Injectable GLP-1 RA Therapy Profiles in Japanese Patients with Type 2 Diabetes: A Discrete Choice Experiment. Advances in Therapy 38:1, pages 721-738.
Crossref
Crossref
Jaime P. Almandoz, Ildiko Lingvay, Javier Morales & Carlos Campos. (2020) Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance. Clinical Diabetes 38:4, pages 390-402.
Crossref
Crossref
Jinsong Geng, Xiaowei Chen, Haini Bao, Danmin Qian, Yuting Shao & Hao Yu. (2020) Patients’ preferences for health insurance coverage of new technologies for treating chronic diseases in China: a discrete choice experiment. BMJ Open 10:9, pages e038051.
Crossref
Crossref
Susan Robinson, Kristina S. Boye, Reema Mody, Alena Antonie Strizek, Manige Konig, Raleigh E. Malik & Tessa Kennedy-Martin. (2020) Real-World Effectiveness of Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Literature Review. Diabetes Therapy 11:7, pages 1437-1466.
Crossref
Crossref
Louis S. Matza, Kristina S. Boye, Katie D. Stewart, Karin S. Coyne, Paula K. Wullenweber, Katelyn N. Cutts, Jessica B. Jordan, Qianqian Wang, Maria Yu, Brooke M. Currie, Karen G. Malley, K. Jack Ishak, Ryan T. Hietpas & Luis‐Emilio García‐Pérez. (2019) Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER). Diabetes, Obesity and Metabolism 22:3, pages 355-364.
Crossref
Crossref